UK markets closed

Shield Therapeutics plc (STX.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
5.95+0.05 (+0.85%)
At close: 05:50PM BST
Currency in GBp

Valuation measures4

Market cap (intra-day) 41.00M
Enterprise value 38.59M
Trailing P/E 53.33
Forward P/E 65.36
PEG ratio (5-yr expected) N/A
Price/sales (ttm)5.44
Price/book (mrq)1.32
Enterprise value/revenue 12.58
Enterprise value/EBITDA -1.80

Trading information

Stock price history

Beta (5Y monthly) 0.83
52-week change 3-70.25%
S&P500 52-week change 3-13.21%
52-week high 321.50
52-week low 35.52
50-day moving average 36.98
200-day moving average 38.18

Share statistics

Avg vol (3-month) 33.13M
Avg vol (10-day) 31.12M
Shares outstanding 5585.67M
Implied shares outstanding 6N/A
Float 8125.07M
% held by insiders 142.23%
% held by institutions 113.58%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in GBP.

Fiscal year

Fiscal year ends 31 Dec 2021
Most-recent quarter (mrq)30 Jun 2022

Profitability

Profit margin 0.00%
Operating margin (ttm)-783.09%

Management effectiveness

Return on assets (ttm)-34.05%
Return on equity (ttm)-57.03%

Income statement

Revenue (ttm)3.07M
Revenue per share (ttm)0.01
Quarterly revenue growth (yoy)322.20%
Gross profit (ttm)539k
EBITDA -22.9M
Net income avi to common (ttm)-23.84M
Diluted EPS (ttm)-0.09
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)2.4M
Total cash per share (mrq)0.01
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)2.60
Book value per share (mrq)0.15

Cash flow statement

Operating cash flow (ttm)-17.46M
Levered free cash flow (ttm)-15.29M